Results 181 to 190 of about 1,456,631 (242)

Real-world outcomes of cefepime/enmetazobactam for Enterobacterales infections: a retrospective descriptive study. [PDF]

open access: yesMicrobiol Spectr
Bonazzetti C   +29 more
europepmc   +1 more source
Some of the next articles are maybe not open access.

Related searches:

Beta-Lactamase Epidemiology and the Utility of Established and Novel Beta-Lactamase Inhibitors.

Expert Opinion on Investigational Drugs, 2000
beta-Lactamase inhibitor:beta-lactam combinations remain one of the most successful strategies for the treatment of bacterial infections. Over the last 20 years the number and diversity of serine and metallo active site beta-lactamases has increased dramatically. This review highlights some of the new additions to the beta-lactamase arena and discusses
David J Payne, D J Payne
exaly   +3 more sources

Beta-Lactams and Beta-Lactamase-Inhibitors in Current- or Potential-Clinical Practice: A Comprehensive Update

open access: yesCritical Reviews in Microbiology, 2009
The use of successive generations of beta-lactams has selected successive generations of beta-lactamases including CTX-M ESBLs, AmpC beta-lactamases, and KPC carbapenamases in Enterobacteriaceae. Moreover, this cephalosporin resistance, along with rising
Haris M Khan, P M Hawkey, M Shahid
exaly   +2 more sources

Beta-lactamase inhibitor combinations

Medical Clinics of North America, 1995
The beta-lactamase inhibitor combinations present a novel approach to the problem of beta-lactamase-induced resistance to antibiotics. These agents are derived from the generally safe beta-lactam class of antibiotics. They are all principally excreted through the kidneys and require dosage adjustment in the face of significant renal insufficiency. They
J W, Sensakovic, L G, Smith
openaire   +2 more sources

Home - About - Disclaimer - Privacy